{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:10Z","timestamp":1788923890415,"version":"build-2803163510"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease. Despite the wide use of conventional synthetic, targeted and biologic disease modifying anti-rheumatic drugs (DMARDs) to control its radiological progress, nearly all DMARDs are immunologically non-selective and do not address the underlying immunological mechanisms of RA. Patients with RA often need to take various DMARDs long-term or even lifelong and thus, face increased risks of infection, tumor and other adverse reactions. It is logical to modulate the immune disorders and restore immune balance in patients with RA by restoring immune tolerance. Indeed, approaches based on stem cell transplantation, tolerogenic dendritic cells (tolDCs), and antigen-based tolerogenic vaccination are under active investigation, and some have already transformed from wet bench research to clinical investigation during the last decade. Among them, clinical trials on stem cell therapy, especially mesenchymal stem cells (MSCs) transplantation are most investigated and followed by tolDCs in RA patients. On the other hand, despite active laboratory investigations on the use of RA-specific peptide-\/protein-based tolerogenic vaccines for T cell, clinical studies on RA patients are much limited. Overall, the preliminary results of these clinical studies are promising and encouraging, demonstrating their safety and effectiveness in the rebalancing of T cell subsets; particular, the recovery of RA-specific Treg with increasing anti-inflammatory cytokines and reduced proinflammatory cytokines. Future studies should focus on the optimization of transplanted stem cells, the preparation of tolDCs, and tolerogenic vaccines with RA-specific protein or peptide, including their dosage, course, and route of administration with well-coordinated multi-center randomized clinical control researches. With the progress of experimental and clinical studies, generating and restoring RA-specific immune tolerance may bring revolutionary changes to the clinical management of RA in the near future.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1012868","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T06:51:28Z","timestamp":1664520688000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Reestablish immune tolerance in rheumatoid arthritis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ziqiang","family":"Shuai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S. C.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2021.1882557","article-title":"Twenty-year changes in mortality rates and underlying causes of death in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"50","author":"Gao","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123524","article-title":"From nsaids to glucocorticoids and beyond","volume":"10","author":"Sinniah","year":"2021","journal-title":"Cells"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30761-3","article-title":"Tapering glucocorticoids in rheumatoid arthritis","volume":"396","author":"Volkmann","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113074","article-title":"Application and pharmacological mechanism of methotrexate in rheumatoid arthritis","volume":"150","author":"Zhao","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-020-00741-3","article-title":"The advances of methotrexate resistance in rheumatoid arthritis","volume":"28","author":"Yu","year":"2020","journal-title":"Inflammopharmacology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.865267","article-title":"Biomarkers to predict dmards efficacy and adverse effect in rheumatoid arthritis","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152909","article-title":"Molecular toxicity of methotrexate in rheumatoid arthritis treatment: A novel perspective and therapeutic implications","volume":"461","author":"Katturajan R","year":"2021","journal-title":"Toxicology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04868-6","article-title":"Systemic toxicity of chloroquine and hydroxychloroquine: Prevalence, mechanisms, risk factors, prognostic and screening possibilities","volume":"41","author":"Muller","year":"2021","journal-title":"Rheumatol Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.mad.2004.06.010","article-title":"Mechanisms of glucocorticoid receptor signaling during inflammation","volume":"125","author":"Smoak","year":"2004","journal-title":"Mech Ageing Dev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez213","article-title":"Effectiveness of different combinations of dmards and glucocorticoid bridging in early rheumatoid arthritis: Two-year results of carera","volume":"58","author":"Stouten","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/life11050457","article-title":"Iguratimod: Novel molecular insights and a new csdmard for rheumatoid arthritis, from Japan to the world","volume":"11","author":"Nozaki","year":"2021","journal-title":"Life (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40744-021-00404-x","article-title":"Differential changes in acpa fine specificity and gene expression in a randomized trial of abatacept and adalimumab in rheumatoid arthritis","volume":"9","author":"Jabado","year":"2022","journal-title":"Rheumatol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: An overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheumatol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04699-8","article-title":"A comprehensive review of rituximab therapy in rheumatoid arthritis patients","volume":"38","author":"Tavakolpour","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000490","article-title":"Sulfasalazine-related hypersensitivity reactions in patients with rheumatic diseases","volume":"23","author":"Cildag","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tox.2017.10.002","article-title":"Endoplasmic reticulum stress and mapk signaling pathway activation underlie leflunomide-induced toxicity in Hepg2 cells","volume":"392","author":"Ren","year":"2017","journal-title":"Toxicology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4555","article-title":"Concomitant use of low-dose methotrexate and nsaids and the risk of serious adverse events among patients with rheumatoid arthritis","volume":"27","author":"Svanstrom","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212086","article-title":"Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological dmards: A Danish population-based cohort study","volume":"77","author":"Dreyer","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11112955","article-title":"Risk of severe infection among rheumatoid arthritis patients on biological dmards: A population-based cohort study","volume":"11","author":"Bellan","year":"2022","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01070","article-title":"Comparative price analysis of biological products for treatment of rheumatoid arthritis","volume":"9","author":"Manova","year":"2018","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/535361","article-title":"Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis","volume":"2012","author":"Chen","year":"2012","journal-title":"J biomedicine Biotechnol"},{"key":"B25","first-page":"S4","article-title":"The central role of T cells in rheumatoid arthritis","volume":"25","author":"Cope","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864403","article-title":"Nanoparticles for inducing antigen-specific T cell tolerance in autoimmune diseases","volume":"13","author":"Benne","year":"2022","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm0710-740","article-title":"The inverse of immunity","volume":"16","author":"Dolgin","year":"2010","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010044","article-title":"Restoring the balance between pro-inflammatory and anti-inflammatory cytokines in the treatment of rheumatoid arthritis: New insights from animal models","volume":"10","author":"Markovics","year":"2021","journal-title":"Biomedicines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.657768","article-title":"Emerging therapeutics for immune tolerance: Tolerogenic vaccines, T cell therapy, and il-2 therapy","volume":"12","author":"Moorman","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103427","article-title":"Mesenchymal Stem\/Stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies","volume":"69","author":"Lopez-Santalla","year":"2021","journal-title":"EBioMedicine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02837","article-title":"Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular pre-conditioning","volume":"9","author":"Ferreira","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu033","article-title":"Mesenchymal stem cells, autoimmunity and rheumatoid arthritis","volume":"107","author":"El-Jawhari","year":"2014","journal-title":"QJM monthly J Assoc Physicians"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/srep12777","article-title":"Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105687","article-title":"Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis","volume":"74","author":"Ma","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cellimm.2014.10.005","article-title":"Paradoxical effects of human adipose tissue-derived mesenchymal stem cells on progression of experimental arthritis in skg mice","volume":"292","author":"Kim","year":"2014","journal-title":"Cell Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.intimp.2017.03.016","article-title":"Human adipose tissue-derived mesenchymal stem cells in rheumatoid arthritis: Regulatory effects on peripheral blood mononuclear cells activation","volume":"47","author":"Baharlou","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-181","article-title":"Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells","volume":"9","author":"Ra","year":"2011","journal-title":"J Trans Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3562753","article-title":"The sufficient immunoregulatory effect of autologous bone marrow-derived mesenchymal stem cell transplantation on regulatory T cells in patients with refractory rheumatoid arthritis","volume":"2020","author":"Ghoryani","year":"2020","journal-title":"J Immunol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/73720","article-title":"Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model","volume":"27","author":"Abdelmawgoud","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-020-09954-z","article-title":"Therapeutic potential of mesenchymal stromal stem cells in rheumatoid arthritis: A systematic review of in vivo studies","volume":"16","author":"Karamini","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144336","article-title":"A significant decrease of baff, April, and baff receptors following mesenchymal stem cell transplantation in patients with refractory rheumatoid arthritis","volume":"732","author":"Gowhari Shabgah","year":"2020","journal-title":"Gene"},{"key":"B43","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13287-019-1307-9","article-title":"Mesenchymal stem cell repression of Th17 cells is triggered by mitochondrial transfer","volume":"10","author":"Luz-Crawford","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"R210","DOI":"10.1186\/ar3187","article-title":"Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis","volume":"12","author":"Liu","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207259.10","article-title":"A1.10 human bone marrow-derived mesenchymal stromal cells strongly inhibit cytokine production by naive, memory and effector Cd4+ and Cd8+ T cells from rheumatoid arthritis patients, independently of disease activity status","volume":"74","author":"Pedrosa","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1038\/s41598-020-60041-2","article-title":"Local transplantation of adipose-derived stem cells has a significant therapeutic effect in a mouse model of rheumatoid arthritis","volume":"10","author":"Ueyama","year":"2020","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-181","article-title":"Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells","volume":"9","author":"Ra","year":"2011","journal-title":"J Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.056","article-title":"Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran","volume":"109","author":"Ghoryani","year":"2019","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/Iia clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.18-0031","article-title":"Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: A phase ia clinical trial","volume":"7","author":"Park","year":"2018","journal-title":"Stem Cells Trans Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s225613","article-title":"Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: A prospective phase I\/Ii study","volume":"13","author":"Wang","year":"2019","journal-title":"Drug design Dev Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/annrheumdis-2017-eular.1106","article-title":"Fri0220 allogeneic mesenchymal precursor cells (Mpcs): A novel approach to treating biologic refractory rheumatoid arthritis","volume":"76","author":"Kafaja","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12967-018-1541-4","article-title":"Serum ifn-\u0393 levels predict the therapeutic effect of mesenchymal stem cell transplantation in active rheumatoid arthritis","volume":"16","author":"Yang","year":"2018","journal-title":"J Trans Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217798","article-title":"Combination of human umbilical cord mesenchymal stem (Stromal) cell transplantation with ifn-\u0393 treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13287-022-02763-w","article-title":"Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: A phase I\/Iia, open-label, non-randomized pilot trial","volume":"13","author":"Vij","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081852","article-title":"Mesenchymal Stem\/Stromal cells for rheumatoid arthritis treatment: An update on clinical applications","volume":"9","author":"Lopez-Santalla","year":"2020","journal-title":"Cells"},{"key":"B57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/Iia clinical trial","volume":"76","author":"Alvaro-Gracia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.056","article-title":"Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran","volume":"109","author":"Ghoryani","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jcyt.2017.12.009","article-title":"Intra-articular knee implantation of autologous bone Marrow 2013;Derived mesenchymal stromal cells in rheumatoid arthritis patients with knee involvement: Results of a randomized, triple-blind, placebo-controlled phase 1\/2 clinical trial","volume":"20","author":"Shadmanfar","year":"2018","journal-title":"Cytotherapy"},{"key":"B60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.it.2020.11.001","article-title":"Tolerogenic dendritic cells in autoimmunity and inflammatory diseases","volume":"42","author":"Morante-Palacios","year":"2021","journal-title":"Trends Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.02.006","article-title":"Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy","volume":"18","author":"Funes","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157970","article-title":"Regulatory macrophages and tolerogenic dendritic cells in myeloid regulatory cell-based therapies","volume":"22","author":"Suuring","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.552988","article-title":"Tolerogenic dendritic cells: The pearl of immunotherapy in organ transplantation","volume":"11","author":"Zhuang","year":"2020","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02068","article-title":"Matured tolerogenic dendritic cells effectively inhibit autoantigen specific Cd4(+) T cells in a murine arthritis model","volume":"10","author":"Jansen","year":"2019","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106275","article-title":"Recent discoveries in dendritic cell tolerance-inducing pharmacological molecules","volume":"81","author":"Svajger","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00674","article-title":"Tolerizing strategies for the treatment of autoimmune diseases: From ex vivo to in vivo strategies","volume":"11","author":"Cauwels","year":"2020","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12967-019-2128-4","article-title":"Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis","volume":"17","author":"Spiering","year":"2019","journal-title":"J Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13578","article-title":"Vasoactive intestinal peptide-induced tolerogenic dendritic cells attenuated arthritis in experimental collagen-induced arthritic mice","volume":"22","author":"Wu","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504484102","article-title":"Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders","volume":"102","author":"Chorny","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.9b00092","article-title":"Combinatorial, microparticle-based delivery of immune modulators reprograms the dendritic cell phenotype and promotes remission of collagen-induced arthritis in mice","volume":"2","author":"Allen","year":"2019","journal-title":"ACS Appl Bio Mater"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900552","article-title":"Tolerogenic dendritic cells generated by baff silencing ameliorate collagen-induced arthritis by modulating the Th17\/Regulatory T cell balance","volume":"204","author":"Zhao","year":"2020","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094885","article-title":"Dendritic cells and their immunotherapeutic potential for treating type 1 diabetes","volume":"23","author":"Khan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107273","article-title":"Dir-labeled tolerogenic dendritic cells for targeted imaging in collagen- induced arthritis rats","volume":"91","author":"Tian","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"290ra87","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in hla risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105164","article-title":"Antigen-specific tolerance approach for rheumatoid arthritis: Past, present and future","volume":"88","author":"Page","year":"2021","journal-title":"Joint Bone Spine"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030309","article-title":"Tolerogenic dendritic cell-based treatment for multiple sclerosis (Ms): A harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration","volume":"9","author":"Willekens","year":"2019","journal-title":"BMJ Open"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8060375","article-title":"Peptide-based vaccination therapy for rheumatic diseases","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050448","article-title":"Vaccination by two derg leaps conjugates incorporating distinct proteoglycan (Pg, aggrecan) epitopes provides therapy by different immune mechanisms in a mouse model of rheumatoid arthritis","volume":"9","author":"Zimmerman","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"17345","DOI":"10.1038\/s41598-021-95193-2","article-title":"A fructosylated peptide derived from a collagen ii T cell epitope for long-term treatment of arthritis (Fia-cia) in mice","volume":"11","author":"Wenhart","year":"2021","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2021.101307","article-title":"Restoring immunological tolerance in established experimental arthritis by combinatorial citrullinated peptides and immunomodulatory signals","volume":"41","author":"Chen","year":"2021","journal-title":"Nano Today"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1593085","article-title":"Vaccination against autoimmune diseases moves closer to the clinic","volume":"16","author":"van Eden","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206803109","article-title":"Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis","volume":"109","author":"van Herwijnen","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.562905","article-title":"Hsp65-producing lactococcocus lactis prevents antigen-induced arthritis in mice","volume":"11","author":"Gusmao-Silva","year":"2020","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.562905","article-title":"Hsp65-producing lactococcocus lactis prevents antigen-induced arthritis in mice","volume":"11","author":"Gusmao-Silva","year":"2020","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41419-020-2632-8","article-title":"Tonebp in dendritic cells mediates pro-inflammatory maturation and Th1\/Th17 responses","volume":"11","author":"Ye","year":"2020","journal-title":"Cell Death Dis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025257118","article-title":"14-3-3zeta: A suppressor of inflammatory arthritis","volume":"118","author":"Kim","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B88","article-title":"A phase I, randomized, double-blind, placebo-controlled, single center, single-dose escalation to investigate the safety, tolerability, and pharmacodynamics of subcutaneously administered den-181 in adult patients with acpa+ rheumatoid arthritis on stable methotrexate","volume":"71","author":"Sonigra","year":"2019","journal-title":". Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1012868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T06:51:36Z","timestamp":1664520696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1012868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2022.1012868"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1012868","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"1012868"}}